Total Funding
20
59
Total FundingPre-Seed raised
Growth Score
-3 pts
Heat Score
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
192966
Next-generation macrocyclic antibody-like drugs for rapid response medical countermeasures
About the Company
Narval develops next-generation of antibody-like drugs using macrocyclic synthetic proteins that mimicthe activity of antibodies and can be delivered through mucosal tissues for localized treatment and non-systemic delivery. Our Antibody Mimetic Proteins, or AMP for short, are developed by fusing CDR3 regions of a single domain shark antibodies toa
conoprotein scaffold from a sea snail, and we optimize their capabilities using AI and ML algorithms. Narval’s AMPs offer a breakthrough solution for fast, accessible, and deployable therapeutics in areas like pandemics, emergency outbreaks, biodefense, animal health, and agricultural biosecurity.
